Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Help & Advice
University of Warwick

The Library

  • Login
  • Admin

Cardiovascular outcomes associated with use of clarithromycin : population based study

Tools
- Tools
+ Tools

Wong, Angel Y. S., Root, Adrian, Douglas, Ian J., Chui, Celine S. L., Chan, Esther W., Ghebremichael Weldeselassie, Yonas, Siu, Chung-Wah, Smeeth, Liam and Wong, Ian C. K. (2016) Cardiovascular outcomes associated with use of clarithromycin : population based study. BMJ, 352 . h6926. doi:10.1136/bmj.h6926

[img]
Preview
PDF
WRAP-cardiovascular-outcomes-associated-use-clarithromycin-Ghebremichael-Weldeselassie-2016.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution 4.0.

Download (854Kb) | Preview
Official URL: http://dx.doi.org/10.1136/bmj.h6926

Request Changes to record.

Abstract

Study question:

What is the association between clarithromycin use and cardiovascular outcomes?

Methods:

In this population based study the authors compared cardiovascular outcomes in adults aged 18 or more receiving oral clarithromycin or amoxicillin during 2005-09 in Hong Kong. Based on age within five years, sex, and calendar year at use, each clarithromycin user was matched to one or two amoxicillin users. The cohort analysis included patients who received clarithromycin (n=108 988) or amoxicillin (n=217 793). The self controlled case series and case crossover analysis included those who received Helicobacter pylori eradication treatment containing clarithromycin. The primary outcome was myocardial infarction. Secondary outcomes were all cause, cardiac, or non-cardiac mortality, arrhythmia, and stroke.

Study answer and limitations:

The propensity score adjusted rate ratio of myocardial infarction 14 days after the start of antibiotic treatment was 3.66 (95% confidence interval 2.82 to 4.76) comparing clarithromycin use (132 events, rate 44.4 per 1000 person years) with amoxicillin use (149 events, 19.2 per 1000 person years), but no long term increased risk was observed. Similarly, rate ratios of secondary outcomes increased significantly only with current use of clarithromycin versus amoxicillin, except for stroke. In the self controlled case analysis, there was an association between current use of H pylori eradication treatment containing clarithromycin and cardiovascular events. The risk returned to baseline after treatment had ended. The case crossover analysis also showed an increased risk of cardiovascular events during current use of H pylori eradication treatment containing clarithromycin. The adjusted absolute risk difference for current use of clarithromycin versus amoxicillin was 1.90 excess myocardial infarction events (95% confidence interval 1.30 to 2.68) per 1000 patients.

What this study adds:

Current use of clarithromycin was associated with an increased risk of myocardial infarction, arrhythmia, and cardiac mortality short term but no association with long term cardiovascular risks among the Hong Kong population.

Item Type: Journal Article
Subjects: R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Medicine > Warwick Medical School > Health Sciences
Faculty of Medicine > Warwick Medical School > Health Sciences > Population, Evidence & Technologies (PET)
Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Antibiotics -- Testing -- Hong Kong, Cardiovascular system -- Diseases, Arrhythmia, Cerebrovascular disease
Journal or Publication Title: BMJ
Publisher: BMJ Publishing Group Ltd.
ISSN: 0959-535X
Official Date: 14 January 2016
Dates:
DateEvent
14 January 2016Available
13 November 2015Accepted
Date of first compliant deposit: 10 May 2018
Volume: 352
Article Number: h6926
DOI: 10.1136/bmj.h6926
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access
RIOXX Funder/Project Grant:
Project/Grant IDRIOXX Funder NameFunder ID
UNSPECIFIEDMedical Research Councilhttp://dx.doi.org/10.13039/501100000265
UNSPECIFIEDWellcome Trusthttp://dx.doi.org/10.13039/100004440

Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics

twitter

Email us: wrap@warwick.ac.uk
Contact Details
About Us